Conatus Pharmaceuticals (Conatus Pharmaceuticals) EV-to-EBIT : -1.80 (As of Apr. 26, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Conatus Pharmaceuticals's Enterprise Value is $18.44 Mil. Conatus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 was $-10.24 Mil. Therefore, Conatus Pharmaceuticals's EV-to-EBIT for today is -1.80.

The historical rank and industry rank for Conatus Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

CNAT's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.41
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Conatus Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2020 was $-7.54 Mil. Conatus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 was $-10.24 Mil. Conatus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2020 was 135.82%.

Conatus Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Conatus Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals EV-to-EBIT Chart

Conatus Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

EV-to-EBIT

Get a 7-Day Free Trial

-0.90

-2.08

-4.61

-0.96

0.61

Conatus Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
EV-to-EBIT	Get a 7-Day Free Trial															-0.15	1.42	0.92	0.61	0.74

Competitive Comparison of Conatus Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Conatus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conatus Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conatus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Conatus Pharmaceuticals's EV-to-EBIT falls into.

Conatus Pharmaceuticals EV-to-EBIT Calculation

Conatus Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	18.443	/	-10.237
	=	-1.80

Conatus Pharmaceuticals's current Enterprise Value is $18.44 Mil.
Conatus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.24 Mil.

Conatus Pharmaceuticals (NAS:CNAT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Conatus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2020 )	=	EBIT	/	Enterprise Value (Q: Mar. 2020 )
	=	-10.237	/	-7.5373
	=	135.82 %

Conatus Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2020 was $-7.54 Mil.
Conatus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.24 Mil.

Conatus Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127

Website

https://www.conatuspharma.com

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.